MEDXF (Medexus Pharmaceuticals) ROCE %: -8.51% (As of Mar. 2026)

What is Medexus Pharmaceuticals ROCE %?

Medexus Pharmaceuticals MEDXF +3.96% 60 ROCE % is -8.51% as of Mar. 2026. GuruFocus rates MEDXF with a GF Score™ of 60/100 and a GF Value™ of $1.32 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medexus Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was -8.51%.

Medexus Pharmaceuticals (OTCPK:MEDXF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medexus Pharmaceuticals ROCE % Related Terms

Medexus Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Medexus Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals ROCE % Chart

Medexus Pharmaceuticals Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

ROCE %

Get a 7-Day Free Trial

8.42

10.14

16.10

11.75

3.48

Medexus Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															6.47	10.82	5.78	8.65	-8.51

60GF Score

Medexus Pharmaceuticals Inc MEDXF

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Medexus Pharmaceuticals ROCE % Calculation

Medexus Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	2.927	/	( ( (171.838 - 97.31)	+	(147.284 - 53.582) )	/ 2 )
	=	2.927	/	( (74.528	+	93.702)	/ 2 )
	=	2.927	/	84.115
	=	3.48 %

Medexus Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-7.924	/	( ( (154.982 - 62.399)	+	(147.284 - 53.582) )	/ 2 )
	=	-7.924	/	( ( 92.583	+	93.702 )	/ 2 )
	=	-7.924	/	93.1425
	=	-8.51 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -8.51% mean?

Medexus Pharmaceuticals (MEDXF) has a ROCE % of -8.51% as of Mar. 2026.

Is Medexus Pharmaceuticals' ROCE % too high?

Medexus Pharmaceuticals' current ROCE % is -8.51%. Overall, Medexus Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Medexus Pharmaceuticals' ROCE % compare to ZTS and UTHR?

Medexus Pharmaceuticals' ROCE % of -8.51% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.03, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medexus Pharmaceuticals's current ROCE % is -8.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Medexus Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Medexus Pharmaceuticals (MEDXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.32, compared to a current price of $3.62 — trading 174.2% above its estimated fair value. The current ROCE % is -8.51%. Medexus Pharmaceuticals' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Medexus Pharmaceuticals (MEDXF), the current ROCE % is -8.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medexus Pharmaceuticals (MEDXF) Overvalued in 2026?

Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued. The current stock price of $3.62 is trading 174.2% above its estimated GF Value™ of $1.32. GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for MEDXF:

ROCE %: -8.51%
GF Value™: $1.32 vs. price of $3.62 (174.2% above fair value)
GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the MEDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medexus Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies XCNQ:JUSH XCNQ:AAWH.U TSX:HLS XCNQ:GRIN TSX:CWEB TSXV:RX XCNQ:NVRS TSX:LOVE TSX:CRDL TSXV:DB XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges P731:Germany MDP:Canada

Address 10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3

Website https://www.medexus.com

Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.

60GF Score

Get the complete analysis for MEDXF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.62

Price

$1.32

GF Value

View MEDXF Analysis

See ROCE % data for all stocks →